[1]王艳新　叶富跃　王　艳.miR-126表达水平及其基因启动子甲基化状态与胶质母细胞瘤术后复发的关系[J].中国临床神经外科杂志,2021,26(09):682-686.[doi:10.13798/j.issn.1009-153X.2021.09.009]
　WANG Yan-xin,YE Fu-yue,WANG Yan..Relationship between miR-126 expression level and its gene promoter methylation status and postoperative recurrence of glioblastoma[J].,2021,26(09):682-686.[doi:10.13798/j.issn.1009-153X.2021.09.009]
点击复制

miR-126表达水平及其基因启动子甲基化状态与胶质母细胞瘤术后复发的关系()
分享到：

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
26
期数:
2021年09期
页码:
682-686
栏目:
论著
出版日期:
2021-09-25

文章信息/Info

Title:
Relationship between miR-126 expression level and its gene promoter methylation status and postoperative recurrence of glioblastoma
文章编号:
1009-153X（2021）09-0682-05
作者:
王艳新　叶富跃　王　艳
570102 海口，海南医学院第一附属医院神经外科（王艳新、叶富跃、王　艳）
Author(s):
WANG Yan-xin;  YE Fu-yue;  WANG Yan.
Department of Neurosurgery, The First Affiliated Hospital of Hainan Medical College,Haikou 570102, China
关键词:
胶质母细胞瘤; miR-126; 基因启动子甲基化; 术后复发; 影响因素
Keywords:
Glioblastoma;  miR-126;  Gene promoter methylation;  Postoperative recurrence
分类号:
R 739.41; Q 786
DOI:
10.13798/j.issn.1009-153X.2021.09.009
文献标志码:
A
摘要:
目的 探讨miR-126表达水平及其基因启动子甲基化状态与胶质母细胞瘤（GBM）术后复发的关系。方法 收集2016年8月到2020年12月手术切除的GBM组织标本86例和同期颅脑损伤内减压术中切除非肿瘤脑组织30例，采用PCR和MSP法检测miR-126表达水平及其基因启动子甲基化状态。随访至2021年3月，随访时间2~56个月，中位随访时间24.0个月。术后定期复查MRI确定肿瘤复发和复发时间。结果 术后58例复发，复发率为67.44%。与非肿瘤脑组织相比，GBM组织miR-126表达水平明显降低（P<0.05），miR-126基因启动子甲基化率明显升高（P<0.05）。与未复发组相比，复发组GBM组织miR-126表达水平明显降低（P<0.05），同时miR-126基因启动子甲基化率明显升高（P<0.05）。生存曲线分析显示，miR-126甲基化组中位复发时间（16.0个月）较非甲基化组（39.0个月）明显缩短（P<0.05）。多因素logistic回归分析显示miR-126基因启动子高甲基化是GBM术后复发的独立危险因素（P<0.05）。ROC曲线分析显示，miR-126表达水平预测GBM术后复发的曲线下面积为0.894（95% CI 0.837~0.950；P<0.05），最佳截断值为0.830，灵敏度和特异度分别为90.0%和75.6%。结论 GBM组织miR-126表达水平普遍降低，与其基因启动子异常甲基化有关。检测miR-126表达水平对GBM术后复发有良好的预测价值。
Abstract:
Objective To investigate the relationship between miR-126 expression level and its gene promoter methylation status and the postoperative recurrence of glioblastoma (GBM). Methods The level of miR-126 and methylation rate of imR-126 gene promoter were detected in GBM tissues obtained from 86 GBM patients who underwent microsurgery from August 2016 to December 2020 and in non-neoplastic cerebral tissues obtained from 30 patients with traumatic brain injury who underwent decompression using PCR and MSP methods, respectively. The deadline for follow-up was March 2021, and the follow-up ranged from 2 months to 56 months with a 24.0-month median follow-up. MRI was reexamined regularly after the surgery to determine tumor recurrence and time to tumor recurrence (TTR). Results Tumor recurrence was occurred in 58 patients (67.44%). Compared with non-neoplastic cerebral tissues, the level of miR-126 in GBM tissues was significantly decreased (P<0.05) and the methylation rate of miR-126 gene promoter was signifcantly increased (P<0.05) in GBM tissues. Compared with the non-relapsed group, the level of miR-126 in GBM tissues was significantly decreased (P<0.05) and the methylation rate of miR-126 gene promoter was signifcantly increased (P<0.05) in relapsed group. Survival curve analysis showed that the median TTR (16.0 months) in the miR-126 methylation group was significantly shorter than that (39.0 months) in the non-methylation group (P<0.05). Multivariate logistic regression analysis showed the hypermethylation of miR-126 gene promoter was an independent risk factor for postoperative recurrence of GBM (P<0.05). ROC curve analysis showed that the area under the curve for miR-126 level to predict postoperative recurrence of GBM was 0.894 (95% CI 0.837~0.950; P<0.05), the best cut-off value was 0.830, and the sensitivity and ecificity were 90.0% and 75.6%, respectively. Conclusions The expression level of miR-126 in GBM tissues generally decreases, which is related to abnormal methylation of its gene promoter. Detection of miR-126 has a good predictive value for postoperative recurrence of GBM.

参考文献/References:

[1] Tan AC, Ashley DM, López GY, et al. Management of glio-blastoma: State of the art and future directions [J]. CA Cancer J Clin, 2020, 70(4): 299-312.
[2] Kong D, Ying B, Zhang J, et al. The anti-osteosarcoma pro-perty of ailanthone through regulation of miR-126/VEGF-A axis [J]. Artif Cells Nanomed Biotechnol, 2019, 47(1): 3913-3919.
[3] 王　凯，张　姝，施　露，等. 2016年世界卫生组织中枢神经系统肿瘤分类概述[J]. 磁共振成像，2016，7（12）：881-896.
[4] Chung JY, Cho H, Hewitt SM. The paraffin-embedded RNA metric (PERM) for RNA isolated from formalin-fixed, paraffin-embedded tissue [J]. Biotechniques, 2016, 60(5):239-244.
[4] 袁　航，屠世良. 结直肠癌组织miR34a启动子区甲基化状态的临床意义探讨[J]. 浙江医学，2019，41（18）：1952-1955.
[5] Zhang X, Zhang W, Mao XG, et al. Malignant intracranial high grade glioma and current treatment strategy [J]. Curr Cancer Drug Targets, 2019, 19(2): 101-108.
[6] 陈寿仁，王占祥，沈上杭，等. miR-126下调MMP-2抑制人脑胶质瘤细胞侵袭[J]. 肿瘤防治研究，2012，39（3）：264-266.
[7] Chen SR, Cai WP, Dai XJ, et al. Research on miR-126 in glioma targeted regulation of PTEN/PI3K/Akt and MDM2-p53 pathways [J]. Eur Rev Med Pharmacol Sci, 2019, 23(8): 3461-3470.
[8] Xu Y, Xu W, Lu T, et al. miR-126 affects the invasion and migration of glioma cells through GATA4 [J]. Artif Cells Nanomed Biotechnol, 2017, 45(6): 1-7.
[9] Klughammer J, Kiesel B, Roetzer T, et al. The DNA methy-lation landscape of glioblastoma disease progression shows extensive heterogeneity in time and space [J]. Nat Med, 2018, 24(10): 1611-1624.
[10] Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1 [J]. Cancer Cell, 2010, 17(1): 98-110.

相似文献/References:

[1]谢宝树　张　林　王　宇　贾　锋　殷玉华.复发性多发胶质母细胞瘤的预后分析[J].中国临床神经外科杂志,2016,(06):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
　XIE Bao-shu,ZHANG Lin,WANG Yu,et al.Analysis of prognoses in patients with recurrent multiple glioblastomas[J].,2016,(09):333.[doi:10.13798/j.issn.1009-153X.2016.06.005]
[2]宋贵东 综述　高之宪 审校.贝伐单抗治疗复发胶质母细胞瘤的研究进展[J].中国临床神经外科杂志,2015,(10):638.[doi:10.13798/j.issn.1009-153X.2015.10.022]
[3]李继强　杨吉安　邵灵敏　吴庭枫　刘宝辉　陈谦学.稳定低表达BAG3的胶质母细胞瘤U87细胞株的构建及鉴定[J].中国临床神经外科杂志,2015,(06):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
　LI Ji-qiang,YANG Ji-an,SHAO Ling-min,et al.Construction and identification of U87 glioblastoma cell strain with a stable low expression of BAG3[J].,2015,(09):353.[doi:10.13798/j.issn.1009-153X.2015.06.011]
[4]桂志勇　冯　军　黄俊红　白敬洋.靶向沉默c-fos基因表达对胶质瘤U87MG细胞增殖与侵袭的影响[J].中国临床神经外科杂志,2017,(12):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
　GUI Zhi-yong,FENG Jun,HUANG Jun-hong,et al.Effects of c-fos targeted silence on proliferation and invasiveness of human glioma cell U87[J].,2017,(09):834.[doi:10.13798/j.issn.1009-153X.2017.12.011]
[5]王娇燕　孟凡华　刘魏然　魏春晓　林丽萍.SWI在胶质母细胞瘤与单发脑转移瘤鉴别中的价值[J].中国临床神经外科杂志,2018,(01):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
　WANG Jiao-yan,MENG Fan-hua,LIU Wei-ran,et al.Value of susceptibility-weighted imaging in differentiative diagnosis of glioblastomas and solitary brain metastases[J].,2018,(09):13.[doi:10.13798/j.issn.1009-153X.2018.01.005]
[6]张治元　王汉东　樊友武　贾　玥　吴晋蓉.胶质肉瘤15例分析及文献复习[J].中国临床神经外科杂志,2018,(02):69.
　ZHANG Zhi-yuan,WANG Han-dong,FAN You-wu,et al.Diagnosis and treatment of gliosarcoma: a report of 15 cases and literature review[J].,2018,(09):69.
[7]郑锐哲　姜秀峰　陈二涛　孙兆良　冯东福.胶质母细胞瘤卒中术后继发硬膜下水瘤1例[J].中国临床神经外科杂志,2019,(02):128.[doi:10.13798/j.issn.1009-153X.2019.02.022]
[8]胡 玥,薛小燕,李子超,等.阿苯达唑抑制胶质瘤裸鼠模型肿瘤生长[J].中国临床神经外科杂志,2019,(06):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
　HU Yue,XUE Xiao-yan,LI Zi-chao,et al.Albendazole inhibits tumor growth in nude mice model of glioma[J].,2019,(09):348.[doi:10.13798/j.issn.1009-153X.2019.06.010]
[9]殷安安　陆　南　贺亚龙　章　翔　刘玉河.TRIM38基因非CpG岛DNA甲基化与胶质母细胞瘤临床预后的关系[J].中国临床神经外科杂志,2020,(02):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
　YIN An-an,LU Nan,HE Ya-long,et al.Impacts of TRIM38 non-CpG island DNA methylation alterations on clinical prognosis in patients with glioblastomas[J].,2020,(09):76.[doi:10.13798/j.issn.1009-153X.2020.02.005]
[10]吴　蛟　易　勇　赵卓琳　周良学　周世军.贝伐珠单抗联合化疗治疗胶质母细胞瘤的meta分析[J].中国临床神经外科杂志,2020,(02):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]
　WU Jiao,YI Yong,ZHAO Zhuo-lin,et al.Efficacy and safety of bevacizumab combined with chemotherapy for glioblastoma: a meta-analysis[J].,2020,(09):82.[doi:10.13798/j.issn.1009-153X.2020.02.007]

更新日期/Last Update: 1900-01-01